Advertisement

Factors that impact on the burden of Escherichia coli bacteraemia: multivariable regression analysis of 2011–2015 data from West London

Published:November 04, 2018DOI:https://doi.org/10.1016/j.jhin.2018.10.024

      Summary

      Background

      The incidence of Escherichia coli bacteraemia in England is increasing amid concern regarding the roles of antimicrobial resistance and nosocomial acquisition on burden of disease.

      Aim

      To determine the relative contributions of hospital-onset E. coli bloodstream infection and specific E. coli antimicrobial resistance patterns to the burden and severity of E. coli bacteraemia in West London.

      Methods

      Patient and antimicrobial susceptibility data were collected for all cases of E. coli bacteraemia between 2011 and 2015. Multivariable logistic regression was used to determine the association between the category of infection (hospital or community-onset) and length of stay, intensive care unit admission, and 30-day all-cause mortality.

      Findings

      E. coli bacteraemia incidence increased by 76% during the study period, predominantly due to community-onset cases. Resistance to quinolones, third-generation cephalosporins, and aminoglycosides also increased over the study period, occurring in both community- and hospital-onset cases. Hospital-onset and non-susceptibility to either quinolones or third-generation cephalosporins were significant risk factors for prolonged length of stay, as was older age. Rates of mortality were 7% and 12% at 7 and 30 days, respectively. Older age, a higher comorbidity score, and bacteraemia caused by strains resistant to three antibiotic classes were all significant risk factors for mortality at 30 days.

      Conclusion

      Multidrug resistance, increased age, and comorbidities were the main drivers of adverse outcome. The rise in E. coli bacteraemia was predominantly driven by community-onset infections, and initiatives to prevent community-onset cases should be a major focus to reduce the quantitative burden of E. coli infection.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hospital Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Oppenheim B.
        Escherichia coli bacteraemia papers.
        J Hosp Infect. 2017; 95: 363-364
        • Wisplinghoff H.
        • Bischoff T.
        • Tallent S.M.
        • Seifert H.
        • Wenzel R.P.
        • Edmond M.B.
        Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.
        Clin Infect Dis. 2004; 39: 309-317
        • Abernethy J.
        • Guy R.
        • Sheridan E.A.
        • Hopkins S.
        • Kiernan M.
        • Wilcox M.H.
        • et al.
        Epidemiology of Escherichia coli bacteraemia in England: results of an enhanced sentinel surveillance programme.
        J Hosp Infect. 2017; 95: 365-375
      1. Public Health England. Voluntary surveillance of bacteraemia caused by Escherichia coli in England: 2008–2015 Health Protection Report Volume 10 Number 19 17 June 2016. Available at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/531989/hpr1916.pdf [last accessed August, 2018].

      2. Public Health England. Annual epidemiological commentary: Gram-negative bacteraemia, MRSA bacteraemia, MSSA bacteraemia and C. difficile infections, up to and including financial year April 2017 to March 2018 . Available at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/724030/Annual_epidemiological_commentary_2018.pdf [last accessed August, 2018].

        • Abernethy J.K.
        • Johnson A.P.
        • Guy R.
        • Hinton N.
        • Sheridan E.A.
        • Hope R.J.
        Thirty day all-cause mortality in patients with Escherichia coli bacteraemia in England.
        Clin Microbiol Infect. 2015; 21 (251.e1–8)
        • Schlackow I.
        • Stoesser N.
        • Walker A.S.
        • Crook D.W.
        • Peto T.E.A.
        • Wyllie D.H.
        • et al.
        Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999–2011.
        J Antimicrob Chemother. 2012; 67: 1514-1524
        • Kim S.-Y.
        • Park Y.-J.
        • Johnson J.R.
        • Yu J.K.
        • Kim Y.-K.
        • Kim Y.S.
        Prevalence and characteristics of Escherichia coli sequence type 131 and its H30 and H30Rx subclones: a multicenter study from Korea.
        Diagn Microbiol Infect Dis. 2016; 84: 97-101
        • Livermore D.M.
        • Hope R.
        • Reynolds R.
        • Blackburn R.
        • Johnson A.P.
        • Woodford N.
        Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?.
        J Antimicrob Chemother. 2013; 68: 2667-2674
        • Global and Public Health Group
        UK 5 Year Antimicrobial (AMR) Strategy 2013–2018 – third annual progress reoprt, 2016.
        2017 (Available at:) ([last accessed August 2018])
        • Bou-Antoun S.
        • Davies J.
        • Guy R.
        • Johnson A.P.
        • Sheridan E.A.
        • Hope R.J.
        Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014.
        Eurosurveillance. 2016; 21: 30329
        • Davies J.
        • Johnson A.P.
        • Hope R.
        Identifying hospital-onset Escherichia coli bacteraemia cases from English mandatory surveillance: the case for applying a two-day post-admission rule.
        J Hosp Infect. 2017; 97: 207-211
        • Marín M.
        • Gudiol C.
        • Garcia-Vidal C.
        • Ardanuy C.
        • Carratalà J.
        Bloodstream infections in patients with solid tumors.
        Medicine (Baltimore). 2014; 93: 143-149
        • Lin J.-N.
        • Chen Y.-H.
        • Chang L.-L.
        • Lai C.-H.
        • Lin H.-L.
        • Lin H.-H.
        Clinical characteristics and outcomes of patients with extended-spectrum β-lactamase-producing bacteremias in the emergency department.
        Intern Emerg Med. 2011; 6: 547-555
        • Fennell J.
        • Vellinga A.
        • Hanahoe B.
        • Morris D.
        • Boyle F.
        • Higgins F.
        • et al.
        Increasing prevalence of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study.
        BMC Infect Dis. 2012; 12: 116
        • Al-Hasan M.N.
        • Juhn Y.J.
        • Bang D.W.
        • Yang H.-J.
        • Baddour L.M.
        External validation of bloodstream infection mortality risk score in a population-based cohort.
        Clin Microbiol Infect. 2014; 20: 886-891
        • Park Y.S.
        • Bae I.K.
        • Kim J.
        • Jeong S.H.
        • Hwang S.
        • Seo Y.-H.
        • et al.
        Risk factors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli bacteremia.
        Yonsei Med J. 2014; 55: 467
        • Lopez-Cerero L.
        • Navarro M.D.
        • Bellido M.
        • Martin-Pena A.
        • Vinas L.
        • Cisneros J.M.
        • et al.
        Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications.
        J Antimicrob Chemother. 2014; 69: 809-814
        • Kaya O.
        • Akcam F.Z.
        • Gonen I.
        • Unal O.
        • Ceylan T.
        Risk factors for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in a Turkish hospital.
        J Infect Dev Ctries. 2013; 7: 507-512
        • Falcone M.
        • Vena A.
        • Mezzatesta M.L.
        • Gona F.
        • Caio C.
        • Goldoni P.
        • et al.
        Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae.
        Ann Ig. 2014; 26: 293-304
        • Chen L.F.
        • Chiu C.-T.
        • Lo J.-Y.
        • Tsai S.-Y.
        • Weng L.-S.
        • Anderson D.J.
        • et al.
        Clinical characteristics and antimicrobial susceptibility pattern of hospitalized patients with community acquired urinary tract infections at a regional hospital in Taiwan.
        Healthcare Infect. 2013; 19: 20-25
        • Roubaud Baudron C.
        • Panhard X.
        • Clermont O.
        • Mentré F.
        • Fantin B.
        • Denamur E.
        • et al.
        Escherichia coli bacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome.
        Epidemiol Infect. 2014; 142: 2672-2683
        • Elixhauser A.
        • Steiner C.
        • Harris D.R.
        • Coffey R.M.
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • van Walraven C.
        • Austin P.C.
        • Jennings A.
        • Quan H.
        • Forster A.J.
        A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.
        Med Care. 2009; 47: 626-633
        • Ministry of Housing Communities and Local Government
        English indices of deprivation 2015.
        2015 (Available at:) ([last accessed August 2018])
        • European Committee on Antimicrobial Susceptibility Testing
        Breakpoint tables for interpretation of MICs and zone diameters.
        2017
        Version: 7.1
        (Available at:) ([last accessed August 2018])
        • Otter J.A.
        • Galletly T.J.
        • Davies F.
        • Hitchcock J.
        • Gilchrist M.J.
        • Dyakova E.
        • et al.
        Planning to halve Gram-negative bloodstream infection: getting to grips with healthcare-associated Escherichia coli bloodstream infection sources.
        J Hosp Infect. 2018 Jul 27; ([Epub ahead of print])
        • Public Health England
        English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report.
        2017 (Available at:) ([last accessed August 2018])
        • Peralta G.
        • Sanchez M.B.
        • Garrido J.C.
        • De Benito I.
        • Cano M.E.
        • Martinez-Martinez L.
        • et al.
        Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
        J Antimicrob Chemother. 2007; 60: 855-863
        • Kennedy K.J.
        • Roberts J.L.
        • Collignon P.J.
        Escherichia coli bacteraemia in Canberra: incidence and clinical features.
        Med J Aust. 2008; 188: 209-213
        • Public Health England
        National enhanced mandatory surveillance of Gram-negative Bacteraemia.
        2017 (Available at:) ([last accessed August 2018])
        • Vihta K.-D.
        • Stoesser N.
        • Llewelyn M.J.
        • Quan T.P.
        • Davies T.
        • Fawcett N.J.
        • et al.
        Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016: a study of electronic health records.
        Lancet Infect Dis. 2018;
        • Melzer M.
        • Welch C.
        Is Escherichia coli bacteraemia preventable?.
        Lancet Infect Dis. 2012; 12: 103-104
        • Laupland K.B.
        • Gregson D.B.
        • Church D.L.
        • Ross T.
        • Pitout J.D.D.
        Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region.
        Clin Microbiol Infect. 2008; 14: 1041-1047
        • Public Health England
        Management and treatment of common infections – antibiotic guidance for primary care: for consultation and local adaptation.
        2017 (Available at:) ([last accessed August 2018])
        • Public Health England
        Diagnosis of urinary tract infections (UTIs) Quick reference guide for primary care: for consultation and local adaptation.
        2017 (Available at:) ([last accessed August 2018])
        • Butler C.C.
        • Francis N.A.
        • Thomas-Jones E.
        • Longo M.
        • Wootton M.
        • Llor C.
        • et al.
        Point-of-care urine culture for managing urinary tract infection in primary care: a randomised controlled trial of clinical and cost-effectiveness.
        Br J Gen Pract. 2018; 68: e268-e278